Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors

Changjiang Huang; Wenzhi Wang; Yao Li; Shijun Zhang; Fancui Meng; Weiren Xu; Jing Yuan; Ligong Chen

doi:10.18632/oncotarget.16427

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors

Changjiang Huang, Wenzhi Wang, Yao Li, Shijun Zhang, Fancui Meng, Weiren Xu, Jing Yuan _ and Ligong Chen

PDF | HTML | How to cite

Oncotarget. 2017; 8:37186-37199. https://doi.org/10.18632/oncotarget.16427

Metrics: PDF 2136 views | HTML 2390 views | ?

Abstract

Changjiang Huang1,2, Wenzhi Wang3, Yao Li2, Shijun Zhang2, Fancui Meng2, Weiren Xu2, Jing Yuan2, Ligong Chen1,4,5

1School of Chemical Engineering and Technology, Tianjin University, Tianjin, China

2Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, Tianjin, China

3School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China

4Collaborative Innovation Center of Chemical Science and Engineering, Tianjin, China

5Tianjin Engineering Research Center of Functional Fine Chemicals, Tianjin, China

Correspondence to:

Jing Yuan, email: [email protected]

Ligong Chen, email: [email protected]

Keywords: thrombosis, thromboembolic diseases, anticoagulants, factor Xa inhibitors, thrombin and docking simulation

Received: November 23, 2016 Accepted: March 10, 2017 Published: March 21, 2017

ABSTRACT

Factor Xa (FXa) plays a significant role in the blood coagulation cascade and is a promising target for anticoagulation drugs. Three oral FXa inhibitors have been approved by FDA for treating thrombotic diseases. In this study, 43 novel compounds were synthesized anthranilamide-based FXa inhibitors aiming to ameliorate the toxicity of traditional FXa inhibitors in clinic. The data indicated that the compounds 6a, 6a-b, 6a-e, 6k, 6k-a and 6k-b showed remarkable FXa inhibitory activity and excellent selectivity over thrombin in vitro. Selected compounds also exhibited anticoagulant activities in vitro consequently and were potent novel anti-coagulators in further.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16427

Publication Alerts

Oncoscience

Post-Publication Promotion

Research Papers:

Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors

Abstract